Literature DB >> 22041578

Systemic lupus erythematosus one disease or many?

N Agmon-Levin1, M Mosca, M Petri, Y Shoenfeld.   

Abstract

Systemic lupus erythematosus (SLE) characterizes by a variety of clinical manifestations and the presence of a wide profile of autoantibodies. This clinical and serological heterogeneity raised the question: is SLE a single disease with varied phenotypes, or a similar phenotype shared by different diseases with diverse pathogenic mechanisms? Herein we debate the clinical, genetic, hormonal and serological differences typically observed in SLE on the one hand, and the numerous similarities between subtypes of this disease on the other. Leading to the conclusion that SLE may be considered not as a single disease but rather as a single syndrome, which defines by a set of signs, symptoms, or phenomena that occur together and suggest a particular abnormality. Additionally, the accumulated knowledge on gene expression pathways, autoantibodies clusters, hormonal and environmental factors associated with SLE may allow a better classification of this syndrome and updating of SLE criteria. This may further allow targeted biologics and other therapies as well as "personalized medicine" to begin.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22041578     DOI: 10.1016/j.autrev.2011.10.020

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  59 in total

Review 1.  Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review.

Authors:  Savino Sciascia; Maria Laura Bertolaccini; Dario Roccatello; Munther A Khamashta; Giovanni Sanna
Journal:  J Neurol       Date:  2014-06-21       Impact factor: 4.849

Review 2.  Autoimmunity in 2011.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-08       Impact factor: 8.667

3.  The spectrum between antiphospholipid syndrome and systemic lupus erythematosus.

Authors:  Nancy Agmon-Levin; Yehuda Shoenfeld
Journal:  Clin Rheumatol       Date:  2014-03       Impact factor: 2.980

Review 4.  TLR7 and TLR9 in SLE: when sensing self goes wrong.

Authors:  T Celhar; R Magalhães; A-M Fairhurst
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

5.  Identification of interferon-inducible genes as diagnostic biomarker for systemic lupus erythematosus.

Authors:  Xuebing Feng; Jing Huang; Yan Liu; Lihui Xiao; Dandan Wang; Bingzhu Hua; Betty P Tsao; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2014-10-26       Impact factor: 2.980

Review 6.  Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis.

Authors:  DeLisa Fairweather; Michelle A Petri; Michael J Coronado; Leslie T Cooper
Journal:  Expert Rev Clin Immunol       Date:  2012-03       Impact factor: 4.473

7.  Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists' practice for the monitoring of glucocorticoid eye toxicity.

Authors:  L Carli; C Tani; F Querci; A Della Rossa; S Vagnani; C Baldini; R Talarico; A d'Ascanio; R Neri; A G Tavoni; S Bombardieri; M Mosca
Journal:  Clin Rheumatol       Date:  2013-03-03       Impact factor: 2.980

8.  The impact of obesity on SLE disease activity: findings from the Southern California Lupus Registry (SCOLR).

Authors:  Phildrich Teh; Bishoy Zakhary; Vaneet K Sandhu
Journal:  Clin Rheumatol       Date:  2018-10-24       Impact factor: 2.980

Review 9.  Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider.

Authors:  Giuseppe Turchetti; Jinoos Yazdany; Ilaria Palla; Edward Yelin; Marta Mosca
Journal:  Clin Exp Rheumatol       Date:  2012-10-16       Impact factor: 4.473

Review 10.  The implication of vitamin D and autoimmunity: a comprehensive review.

Authors:  Chen-Yen Yang; Patrick S C Leung; Iannis E Adamopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.